Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with US biotech company BioMap, an AI-based drug discovery platform co-founded by Baidu’s CEO Robin Li and Baidu Ventures CEO Wei Liu. This collaboration aims to develop an AAV assembly efficiency model and assembly distribution model, leveraging BioMap’s unique adeno-associated virus (AAV) vector technology platform and research data.
AAV Vector Technology and AI Models
BioMap, established in 2020, has secured over USD 100 million in Series A financing and has formed partnerships with industry players such as Sanofi, Cellomics Bio, Harbour Bio, GenomiCare Bio, Precision Scientific, and Neowise Bio. The company will utilize its expertise to develop models that enhance AAV assembly efficiency and distribution, which are crucial for advancing gene therapy applications.
Porton Biologics’ Comprehensive CDMO Services
Porton Biologics, founded in 2018, offers an end-to-end CDMO service platform for gene and cell therapy. Its services cover a wide range of therapeutic areas, including plasmids, cell therapy, gene therapy, oncolytic viruses, nucleic acid therapy, and live bacterial therapy. This comprehensive platform positions Porton as a key player in the gene and cell therapy sector.
Joint Acceleration of AAV Vector Design
Both Suzhou Porton Biologics and BioMap aim to harness the power of life science models to jointly accelerate the design of AAV vectors, which are essential for gene therapy. The application of AI models in this field is expected to expand, leading to more efficient and targeted treatments for various genetic disorders.
